Quality of life of people living with HIV and AIDS and antiretroviral therapy

HIV/AIDS - Research and Palliative Care

Volumn 4, Issue , 2012, Pages 117-124

  Oguntibeju, Oluwafemi O ^a  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

Author keywords

Benefits; Modifications of desires; Negative effects; Oxidative stress; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; FIALURIDINE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL PRACTICE; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEALTH SERVICE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SAFETY; PATIENT SATISFACTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84872905207     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S32321     Document Type: Review

References (70)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the Global AIDS Epidemic. Geneva: UNAIDS; 2008.
2. Cadman J, Arboleda C. Once or Twice: A Guide to Medication Dos-ing for HIV Infection. Washington: National Minority AIDS Council; 2001.
3. Shen L, Peterson S, Sedaghat A, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762-766.
4. Weller I V, Williams IG. ABC of AIDS: antiretroviral drugs. BMJ. 2001;322:1410-1412.
5. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-1035.
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Sys-tematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guide-lines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington: Department of Health and Human Services; 2011.
8. Cox S W, Apéria K, Albert J, Wahren B. Comparison of the sensi-tivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses. 1994; 10:1725-1729.
9. Elion RA, Witt MD. Nucleoside and nucleotide reverse transcriptase inhibitors in the treatment of HIV: focus on effcacy. 2003. Available from: http://www.medscape.org/viewarticle/465383_1. Accessed May 18, 2012.
10. Newell M. A Guide to Rating Scales and Questionnaires. New York: Oxford University Press; 1987.
11. Fanning M. Validation of a Quality of Life Instrument for Patients with HIV Infection. Ottawa: Health and Welfare Canada; 1994.
12. Aranda-Naranjo B. Quality of life in HIV-positive patients. J Assoc Nurses AIDS Care. 2004;15:20-27.
13. Friedland J, Rewick R, McColl M. Coping and social support as determinants of quality of life in HIV/AIDS. AIDS Care. 1996;8:15-31.
14. Swindells S, Mohr J, Justis JC, Berman S, Squier C, Wagener MM. Quality of life in patients with human immunodeficiency virus infec-tion: impact of social support, coping style and hopelessness. Int J STD AIDS. 1999;10:383-391.
15. Marins JRP, Jamal LF, Chen SY, et al. Dramatic improve-ment in survival among adult Brazilian AIDS patients. AIDS. 2003;17:1675-1682.
16. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early and late HAART eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
17. Burgoyne RW, Tan DH. Prolongation and quality of life for HIV-infected adults treated with HAART: A balancing act. J Animicrob Chemother. 2008;61:469-473.
18. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS. 2005;17:10-22.
19. Campos LN, César CC, Guimarães MDC. Quality of life among HIV-infected patients in Brazil after initiation of treatment. Clinics (Sao Paulo). 2009;64:867-875.
20. Carr AJ, Thompson P W, Kirwan JR. Quality of life measures. Br J Rheumatol. 1996;35:275-281.
21. Crane HM, Van Rompaey SE, Dillingham PW, Herman E, Diehr P, Kitahata MM. A single-item measure of health-related quality of life for HIV-infected patients in routine clinical care. AIDS Patient Care STDS. 2000;20:161-174.
22. Fleck MPA, Lima AFB, Louzada S, et al. Association of depressive symptoms and social functioning in primary care service, Brazil. Rev Saude Publica. 2002;36:431-438.
23. Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32:38-47.
24. Jia H, Uphold CR, Wu S, Chen GJ, Duncan P W. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS. 2005;19:395-405.
25. Kemppainem JK. Predictors of quality of life in AIDS patients. J Assoc Nurses AIDS Care. 2001;12:61-70.
26. Tostes MA, Chalub M, Botega NJ. The quality of life of HIV-infected women is associated with psychiatric morbidity. AIDS Care. 2004;16:177-186.
27. Chan KS, Orlando M, Joyce G, et al. Combination antiretroviral therapy and improvements in mental health: results from a nationally representa-tive sample of persons undergoing care for HIV in the United States. J Acquir Immune Defic Syndr. 2003;33:104-111.
28. Preau M, Leport C, Salmon-Ceron D, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care. 2004;16:649-661.
29. Wu AW. Quality of life assessment comes of age in the era of HAART. AIDS. 2000;14:1449-1451.
30. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
31. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibi-tor therapy and outcomes in patients with HIV infection. Ann Int Med. 2000;133:21-30.
32. Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combina-tion antiretroviral therapy. HIV Med. 2002;3:118-124.
33. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
34. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JAG. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
35. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consis-tency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
36. Nieuwkerk PT, Reijers MH, Weight HM, Lange JM, Sprangiers MA. Quality of life in maintenance versus prolonged induction for HIV. JAMA. 2000;284:178-179.
37. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Defic Syndr. 2002;29:244-253.
38. Prieto-Flores ME, Fernández-Mayoralas G, Rojo-Pérez F, et al. Effects of sociodemographic factors on emotional and psycho-logical status of HIV/AIDS patients on ART. Rev Esp Salud Publica. 2008;82:301-313.
39. Liu C, Johnson L, Ostrow D, Silvestre A, Visscher B, Jacobson L P. Predictors for lower quality of life in the HAART era among HIV-infected men. J Acquir Immune Defic Syndr. 2006;42:470-477.
40. Wouters E, Heunis C, Van rensburg D, Meulemans H. Physical and emotional health outcomes after 12 months of public-sector antiretro-viral treatment in the Free State Province of South Africa: a longitu-dinal study using structural equation modelling. BMC Public Health. 2009;9:103.
41. Kohli RM, Sane S, Kumar K, Paranjape RS, Mehendale SM. Modifica-tion of medical outcome study (MOS) instrument for QOL assessment and its validation in HIV infected individuals in India. Indian J Med Res. 2005;122:297-304.
42. Badia X, Podzamczer D, Garcia M, López-Lavid C C, Consiglio E. A randomized study comparing instruments for measuring health related quality of life in HIV-infected patients. AIDS. 2001;13:1727-1735.
43. Gill CJ, Griffth JL, Jacobson D, Skinner S, Gorbach SL, Wilson IB. Relationship of HIV viral loads, CD4 counts and HAART use to health related quality of life. J Acquir Immune Defic Syndr. 2002;30:485-492.
44. Campsmith MI, Nakashima AK, Davidson AJ. Self reported health related quality of life in persons with HIV infection:results from multi-sites interview project. Health Qual Life Outcomes. 2003;1:12.
45. Wu, AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
46. Ware JE, Kosinski M, Gandek B. The factor structure of SF-36 health survey in 10 countries: results from the IQOLA project. International Quality of Life Assessment. J Clin Epidemiol. 1997;51:1159-1165.
47. Paton NI, Chapman CA, Chan S P, et al. Validation of the Medical Out-come Study HIV Health Survey as a measure of quality of life in HIV-infected patients in Singapore. Int J STD AIDS. 2002;13:456-461.
48. Smith MY, Feldman J, Kelly P, DeHovitz JA, Chirgwin K, Minkoff H. Health-related quality of life of HIV-infected women: evidence for the reliability, validity and responsiveness of the Medical Outcomes Study Short-Form 20. Qual Life Res. 1996;5:47-55.
49. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
50. Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predic-tors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004;18:281-286.
51. Fiore S, Heard I, Thorne G, Savasi V, Coll RL, Miu A. Fertility desires and intention of HIV-positive women living in Europe. Hum Reprod. 2001;23:2140-2144.
52. Bah'him YM, Oguntibeju OO, Lewis HA, Mokwena K. Factors associated with pregnancies among HIV-positive women on preven-tion of mother-to-child transmission programme. West Indian Med J. 2010;59:362-368.
53. Myer L, Carter RJ, Katyal M, et al. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med. 2010;7:137.
54. Kaida A, Andia I, Maier M, et al. The potential impact of antiretro-viral therapy on fertility in sub-Saharan Africa. Curr HIV/AIDS Rep. 2006;3:187-194.
55. Kaida A, Gray G, Bastos FI, et al. The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa and Uganda. AIDS Care. 2008;20:21-25.
56. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline M W. Growth in HIV-infected receiving antiretroviral therapy at a pae-diatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22:245-251.
57. Murata H, Hruz PW, Muecker M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-20254.
58. Liang JS, Dister O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteosome: a potential mechanism for protease inhibitor-induced hyperlipidaemia. Nat Med. 2001;7:1327-1331.
59. Blumer RM, van Vonderen MG, Sutinen J, et al. Zidovudine-lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227-236.
60. Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22:1561-1568.
61. Marin A, Casado JL, Aranzabal L, et al. Validation of a specific ques-tionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res. 2006;15:767-775.
62. Ammassari A, Murri R, Pezzotti, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiret-roviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
63. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretro-viral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
64. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do pro-tease inhibitor increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
65. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
66. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infections and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
67. Ngondi JL, Oben J, Forkah DM, Etame LU, Mbanya D. The effect of different combination therapies on oxidative stress markers in HIV-infected patients in Cameroon. AIDS Res Ther. 2006;3:1-7.
68. Allard J P, Aghdassi E, Chau J, et al. Effects of vitamin E and C supple-mentation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12:1653-1659.
69. Sen SK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul. 2000;36:1-30.
70. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res. 1999;31:273-300.